Skip to content

News

Nob Hill Therapeutics Expands Strategic Advisory Board with Two Distinguished Leaders in Respiratory Drug Development and Pulmonary Medicine

June 15, 2025 – Albuquerque, NM – NHT is pleased to announce the addition of two prominent experts to its Strategic Advisory Board: Dr. Mark Parry-Billings, a seasoned biotech and pharmaceutical executive with extensive experience in respiratory drug development and Dr. Scott L. Shofer, a physician-scientist and critical care specialist affiliated with Duke University Hospital with deep expertise in pulmonary and interstitial lung disease. Read More >>

Nob Hill Therapeutics Secures Series A Funding to Advance Breakthrough Respiratory Technologies

August 6, 2024 – Albuquerque. NM,  Nob Hill Therapeutics (NHT), an early-stage pulmonary medical device and therapeutics company, today announced the first close of a $3 million Series A financing round. he round was led by new investor Tramway Venture Partners and included investments from TCA Venture Group and VIC Technology Venture Development. Read More >>

Nob Hill Therapeutics Awarded HHS Phase II Grant for Lung Cancer Therapy

October 3, 2023 – Albuquerque. NM,  Nob Hill Therapeutics (NHT), a VIC Technology Venture Development portfolio company, announced today that it has received an HHS phase II grant (up to $2M) to develop an inhaled therapy to treat lung cancer…. Read More >>

Nob Hill Therapeutics Selected for Featured Poster Presentation at Respiratory Innovation Summit

May 18, 2023 – Albuquerque. NM,  Nob Hill Therapeutics (NHT), an inhalation technology company, today announced that it has been selected to be a featured poster presentation at the ATS 2023 Respiratory Innovation Summit (RIS). The RIS will be held in Washington, DC from May 19-20, 2023… Read More >>

Dr. Davies-Cutting Brings Industry Leading Technical Expertise to Nob Hill Therapeutics

October 14, 2022 – Albuquerque. NM, Nob Hill Therapeutics announced today the appointment of Craig Davies-Cutting, PhD, as Vice President of Research and Development. Dr. Davies-Cutting will contribute his extensive respiratory product… Read More >>

Nob Hill Therapeutics Awarded HHS Phase II Grant and Announces New CEO

August 23, 2022 – Nob Hill Therapeutics (NHT), a VIC Technology Venture Development portfolio company, announced today that it has received an HHS phase II grant (up to $1.73M) to develop an inhaled therapy to treat lung fungal infection using an innovative first-of-its-kind dry powder nebulizer delivery platform technology. … Read More >>

Nob Hill Therapeutics: Transforming Drug Delivery for Pulmonary Conditions

May 1, 2022 – Inhalation therapies, despite their prevalence in treating pulmonary diseases and respiratory-related conditions, have numerous setbacks, such as the deposition of aerosolized particles in the upper airway.. Read More >>

Startups to Watch, Nob Hill Therapeutics

February 16, 2022 – This special section marks the launch of the annual Startups to Watch list, a collection of startups New Mexico Inno will keep an eye on in the next 12 months…. Read More >>

Nob Hill Therapeutics Announces Strategic Advisory Board to Accelerate Growth

November 16, 2021 – Nob Hill Therapeutics has recruited global thought leaders to its Strategic Advisory Board. Albuquerque, NM – Nob Hill Therapeutics (NHT) is pleased to announce the members of its Strategic Advisory Board…. Read More >>

Nob Hill Therapeutics to Present at Partnership Opportunities in Drug Delivery (PODD) Conference

October 28, 2021 – Nob Hill Therapeutics’ Executive Chairman Paul Atkins will be presenting at the Partnership Opportunities in Drug Delivery (PODD) conference during the DryNeb – Advancing Pulmonary Drug Delivery session on Friday, October 29th at 12:00pm ET… Read More >>

Albuquerque Biotech Company Commercializing Nebulizer Technology to Deliver Medicine More Efficiently

October 19, 2021 – An Albuquerque biotech company says patients can use its technology to deliver medication to patients’ respiratory system with hardly any effort. The startup, Nob Hill Therapeutics, is aiming to commercialize a nebulizer that disaggregates powdered particles, spreading them out.. Read More >>

Nob Hill Therapeutics Selected as a Finalist for RESI Innovator’s Pitch Challenge

September 17, 2021 – Nob Hill Therapeutics was selected as a finalist in the Redefining Early Stage Investments (RESI) Innovator’s Pitch Challenge (IPC). An opportunity for early-stage companies to gain exposure to conference attendees,… Read More >>

Nob Hill Therapeutics Adds Seasoned Life Science Expert Paul Atkins as Executive Chairman

April 19, 2021 – Atkins will bring critical insight into the development and commercialization of inhaled medicines. Albuquerque, New Mexico – Southwest-based start-up Nob Hill Therapeutics is pleased to announce that Dr. Paul Atkins has been appointed as its Executive Chairman…. Read More >>

VIC Portfolio Companies and Pipeline Technologies with Pandemic Impact

April 15, 2020 – Our current daily activities bear little resemblance to the routines as of as recently as a month ago. COVID-19 has had an obvious and significant impact on the American people. For those suffering from chronic conditions such as dementia, diabetes, heart and respiratory disease, the health impact during traumatic periods such as this is magnified. … Read More >>